Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of APL-1501 vs APL-1202 in Healthy Volunteers
NCT04601766Phase 1Completed
- Sponsor
- Asieris Pharmaceuticals
- Start
- Oct 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of APL-1202 + APL-1501 in bladder cancer (2 arms), sponsored by Asieris Pharmaceuticals. Primary endpoints: Adverse Events at 6 months and Serious Adverse Events at 6 months. Started Oct 2020; status: completed.
02
Drugs
APL-1202 + APL-1501
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT04601766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04601766.